Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-5029 in HER2-Expressing Advanced Solid Tumors
NCT05511844Phase 1Terminated
- Sponsor
- Orum Therapeutics
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ORM-5029 in breast cancer and solid tumor (2 arms), sponsored by Orum Therapeutics. Primary endpoints: Maximum Tolerated Dose at 18 months, Incidence of Adverse Events at 30 months and 2 more. Started Oct 2022; status: terminated.
02
Drugs
ORM-5029
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05511844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511844.